The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study
Open accessAbstract
Background Corona Virus Disease 2019 (COVID-19) due to the 2019 novel coronavirus (SARS-CoV-2) emerged in Wuhan city and rapidly spread throughout China. We aimed to compare arbidol and lopinavir/ritonavir(LPV/r) treatment for patients with COVID-19 with LPV/r only. Methods In this retrospective cohort study, we included adults (age≥18years) with laboratory-confirmed COVID-19 without Invasive ventilation, diagnosed between Jan 17, 2020, and Feb 13, 2020. Patients, diagnosed after Jan 17, 2020, were given oral arbidol and LPV/r in the combination group and oral LPV/r only in the monotherapy group for 5–21 days. The primary endpoint was a negative conversion rate of coronavirus from the date of COVID-19 diagnosis(day7, day14), and assessed whether the pneumonia was progressing or improving by chest CT (day7). Results We analyzed 16 patients who received oral arbidol and LPV/r in the combination group and 17 who oral LPV/r only in the monotherapy group, and both initiated after diagnosis. Baseline clinical, laboratory, and chest CT characteristics were similar between groups. The SARS-CoV-2 could not be detected for 12(75%) of 16 patients’ nasopharyngeal specimens in the combination group after seven days, compared with 6 (35%) of 17 in the monotherapy group (p < 0·05). After 14 days, 15 (94%) of 16 and 9 (52·9%) of 17, respectively, SARS-CoV-2 could not be detected (p < 0·05). The chest CT scans were improving for 11(69%) of 16 patients in the combination group after seven days, compared with 5(29%) of 17 in the monotherapy group (p < 0·05). Conclusion In patients with COVID-19, the apparent favorable clinical response with arbidol and LPV/r supports further LPV/r only.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
Self-citationA pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30211-7 · Cited by 21,415
Self-citationWang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., et al. (2020) · JAMA · doi:10.1001/jama.2020.1585 · Cited by 20,148
Self-citationLa certeza de lo impredecible: Cultura Educación y Sociedad en tiempos de COVID19
Martínez González, M. (2020) · DSPACE System - Metalibrary (University of the Coast) · Cited by 18,463
Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Wang, W., Song, H., Huang, B., Zhu, N., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30251-8 · Cited by 11,907
Chan, J. F.-W., Yuan, S., Kok, K.-H., To, K. K.-W., Chu, H., Yang, J., Xing, F., Liu, J., Yip, C. C.-Y., Poon, R. W.-S., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30154-9 · Cited by 8,944
Pathological findings of COVID-19 associated with acute respiratory distress syndrome
Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., Liu, S., Zhao, P., Liu, H., Zhu, L., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30076-x · Cited by 8,545
Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China
Zhang, J.-J., Dong, X., Cao, Y.-Y., Yuan, Y.-D., Yang, Y.-B., Yan, Y.-Q., Akdis, C. A., & Gao, Y.-D. (2020) · Allergy · doi:10.1111/all.14238 · Cited by 4,004
Metlay, J. P., Waterer, G. W., Long, A. C., Anzueto, A., Brozek, J., Crothers, K., Cooley, L. A., Dean, N. C., Fine, M. J., Flanders, S. A., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201908-1581st · Cited by 3,657 · cited 1×
“Curr Med Chem 2008; 15 (10):997–1005 2008-01-20 .”
CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV)
Chung, M., Bernheim, A., Mei, X., Zhang, N., Huang, M., Zeng, X., Cui, J., Xu, W., Yang, Y., Fayad, Z. A., et al. (2020) · Radiology · doi:10.1148/radiol.2020200230 · Cited by 2,751
Peiris, J., Chu, C., Cheng, V., Chan, K., Hung, I., Poon, L., Law, K., Tang, B., Hon, T., Chan, C., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13412-5 · Cited by 2,375
Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings
Chu, C. M. (2004) · Thorax · doi:10.1136/thorax.2003.012658 · Cited by 1,645
A Novel Coronavirus Emerging in China — Key Questions for Impact Assessment
Munster, V. J., Koopmans, M., van Doremalen, N., van Riel, D., & de Wit, E. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2000929 · Cited by 1,415
SARS: systematic review of treatment effects
Stockman, L. J., Bellamy, R., & Garner, P. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030343 · Cited by 1,217
Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome
Arabi, Y. M., Mandourah, Y., Al-Hameed, F., Sindi, A. A., Almekhlafi, G. A., Hussein, M. A., Jose, J., Pinto, R., Al-Omari, A., Kharaba, A., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201706-1172oc · Cited by 1,122
Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme
Harmer, D., Gilbert, M., Borman, R., & Clark, K. L. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)03640-2 · Cited by 852
Addendum: A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2951-z · Cited by 713
Omrani, A. S., Saad, M. M., Baig, K., Bahloul, A., Abdul-Matin, M., Alaidaroos, A. Y., Almakhlafi, G. A., Albarrak, M. M., Memish, Z. A., & Albarrak, A. M. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70920-x · Cited by 493
Molina, J.-M., Andrade-Villanueva, J., Echevarria, J., Chetchotisakd, P., Corral, J., David, N., Moyle, G., Mancini, M., Percival, L., Yang, R., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61081-8 · Cited by 486
Arbidol as a broad-spectrum antiviral: An update
Blaising, J., Polyak, S. J., & Pécheur, E.-I. (2014) · Antiviral Research · doi:10.1016/j.antiviral.2014.04.006 · Cited by 485
Lopinavir/Ritonavir: A Review of its Use in the Management of HIV Infection
Cvetkovic, R. S., & Goa, K. L. (2003) · Drugs · doi:10.2165/00003495-200363080-00004 · Cited by 436
Arbidol: A Broad-Spectrum Antiviral Compound that Blocks Viral Fusion
Boriskin, Y., Leneva, I., Pecheur, E.-I., & Polyak, S. (2008) · Current Medicinal Chemistry · doi:10.2174/092986708784049658 · Cited by 410
Khamitov, R. A., Loginova, S. I., Николаевна, Щ. В., Borisevich, S. V., Maksimov, V. A., & Shuster, A. M. (2008) · PubMed · Cited by 171
A review of treatment modalities for Middle East Respiratory Syndrome
Mo, Y., & Fisher, D. A. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw338 · Cited by 99
Recent Developments in Anti-Severe Acute Respiratory Syndrome Coronavirus Chemotherapy
Barnard, D. L., & Kumaki, Y. (2011) · Future Virology · doi:10.2217/fvl.11.33 · Cited by 98
Yadav, A. R., & Mohite, S. K. (2020) · Research Journal of Pharmaceutical Dosage Forms and Technology · doi:10.5958/0975-4377.2020.00030.0 · Cited by 88
Cited by
Hung, I. F.-N., Lung, K.-C., Tso, E. Y.-K., Liu, R., Chung, T. W.-H., Chu, M.-Y., Ng, Y.-Y., Lo, J., Chan, J., Tam, A. R., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31042-4 · Cited by 1,455
Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis
Langford, B. J., So, M., Raybardhan, S., Leung, V., Soucy, J.-P. R., Westwood, D., Daneman, N., & MacFadden, D. R. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.12.018 · Cited by 876
Sharma, A., Tiwari, S., Deb, M. K., & Marty, J. L. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.106054 · Cited by 705
An Update on Current Therapeutic Drugs Treating COVID-19
Wu, R., Wang, L., Kuo, H.-C. D., Shannar, A., Peter, R., Chou, P. J., Li, S., Hudlikar, R., Liu, X., Liu, Z., et al. (2020) · Current Pharmacology Reports · doi:10.1007/s40495-020-00216-7 · Cited by 599
Self-citationCandidate drugs against SARS-CoV-2 and COVID-19
McKee, D. L., Sternberg, A., Stange, U., Laufer, S., & Naujokat, C. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104859 · Cited by 562
Metadata
- Authors
- Deng, L., Li, C., Zeng, Q., Liu, X., Li, X., Zhang, H., Hong, Z., & Xia, J.
- Venue
- Journal of Infection
- Publisher
- Elsevier BV
- Published
- 2020-07
- Volume
- 81
- Issue
- 1
- Pages
- e1-e5
- ISSN
- 0163-4453 (ISSN-L)
- OpenAlex
- W3009881183
- Cited by
- 505
- References
- 27
- FWCI
- 14.79
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.